SCHEMBL5504722

SCHEMBL5504722

COc1cc(OC)cc(C(=O)Nc2ccc(C)c(-c3ccc4nc(Nc5ccc(N6CCN(C)CC6)cc5)ncc4c3)c2)c1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LCK P06239 10/20 0.68
MAPK14 Q16539 10/20 0.68
KDR P35968 8/20 0.68
CSF1R P07333 2/20 0.51
DAPK1 P53355 1/20 0.51
BRD4 O60885 2/20 0.50
DDR2 Q16832 2/20 0.50
TEK Q02763 2/20 0.48
ABL1 P00519 2/20 0.48
JAK3 P52333 1/20 0.48
RIPK1 Q13546 1/20 0.48
RIPK3 Q9Y572 1/20 0.48
MAP4K1 Q92918 1/20 0.47
SRC P12931 2/20 0.47
JAK2 O60674 1/20 0.47
FYN P06241 1/20 0.47
LYN P07948 1/20 0.47
MAPK9 P45984 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5497043 0.87 LCK (0.67) LCKMAPK14KDRCSF1RBRD4
SCHEMBL5497607 0.86 LCK (0.61) LCKMAPK14KDRBRD4DDR2
SCHEMBL5494938 0.83 DDR2 (0.54) LCKMAPK14KDRBRD4DDR2
SCHEMBL5488920 0.83 LCK (0.56) LCKMAPK14KDRCSF1RBRD4
SCHEMBL5498378 0.83 LCK (0.70) LCKMAPK14KDRCSF1RBRD4
SCHEMBL5490648 0.82 LCK (0.53) LCKMAPK14KDRCSF1RBRD4
SCHEMBL2951411 0.81 LCK (1.00) LCKMAPK14KDRCSF1RBRD4
SCHEMBL5502952 0.80 LCK (0.71) LCKMAPK14KDRCSF1RDDR2
SCHEMBL5498684 0.80 LCK (0.62) LCKMAPK14KDRCSF1RDDR2
SCHEMBL5494435 0.80 MAP4K1 (0.57) BRD4MAP4K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP claimed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US claimed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 LCK 106/4885MAPK14 301/4885KDR 1044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.